Teniposide
![Teniposide Structure](CAS/GIF/29767-20-2.gif)
- CAS No.
- 29767-20-2
- Chemical Name:
- Teniposide
- Synonyms
- etp;vehem;vm-26;Vumon;Eniposide;nsc122819;Teniposid;Tenoposide;nsc-122819;TENIPOSIDE
- CBNumber:
- CB0455475
- Molecular Formula:
- C32H32O13S
- Molecular Weight:
- 656.65
- MOL File:
- 29767-20-2.mol
- MSDS File:
- SDS
- Modify Date:
- 2023/6/30 15:45:59
Melting point | 244-247°C |
---|---|
Boiling point | 650.86°C (rough estimate) |
alpha | D20 -107° (9:1 chloroform/methanol) |
Density | 1.2568 (rough estimate) |
refractive index | 1.5530 (estimate) |
storage temp. | -20°C |
solubility | DMSO: soluble10mg/mL, clear |
pka | 10.13(at 25℃) |
form | powder |
color | white to beige |
optical activity | [α]/D -100 to -115°, c = 1 in chloroform/methanol (9:1) |
λmax | 283nm(MeOH)(lit.) |
Merck | 14,9145 |
Stability | Hygroscopic |
CAS DataBase Reference | 29767-20-2(CAS DataBase Reference) |
IARC | 2A (Vol. 76) 2000 |
SAFETY
Risk and Safety Statements
Symbol(GHS) | ![]() GHS08 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Signal word | Warning | |||||||||
Hazard statements | H341-H412 | |||||||||
Precautionary statements | P202-P273-P280-P308+P313-P405-P501 | |||||||||
Hazard Codes | Xi,T | |||||||||
Risk Statements | 36/37/38-45 | |||||||||
Safety Statements | 26-36-45-53 | |||||||||
RIDADR | UN 2811 6.1 / PGIII | |||||||||
WGK Germany | 3 | |||||||||
RTECS | KC0180000 | |||||||||
HS Code | 29349990 | |||||||||
Toxicity | LD50 intraperitoneal in mouse: 29570ug/kg | |||||||||
NFPA 704 |
|
Teniposide price More Price(4)
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
Sigma-Aldrich(India) | SML0609 | Teniposide ≥97% (HPLC) | 29767-20-2 | 10MG | ₹7653.28 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | SML0609 | Teniposide ≥97% (HPLC) | 29767-20-2 | 50MG | ₹30645.58 | 2022-06-14 | Buy |
TCI Chemicals (India) | T3109 | Teniposide | 29767-20-2 | 20MG | ₹3400 | 2022-05-26 | Buy |
TCI Chemicals (India) | T3109 | Teniposide | 29767-20-2 | 100MG | ₹12700 | 2022-05-26 | Buy |
Teniposide Chemical Properties,Uses,Production
Chemical Properties
White Solid
Uses
Teniposide is a podophyllotoxin derivative that causes dose-dependent single- and double-stranded breaks in DNA by inhibiting topoisomerase II. Its cytostatic effects are related to its ability to stabilize the DNA-topoisomerase II complex during DNA replication, inducing DNA damage and cellular apoptosis. Teniposide has been widely used in the treatment of various cancers including, small cell lung cancer, malignant lymphoma, breast cancer, oral squamous cell carcinoma, and acute lymphoblastic leukemia.
Indications
Teniposide (VM-26, Vumon) is closely related to etoposide in structure, mechanisms of action and resistance, and adverse effects. It is more lipophilic and approximately threefold more potent than etoposide. Its major uses have been in pediatric cancers, particularly in acute lymphoblastic leukemias.
Definition
ChEBI: A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.
General Description
Teniposide is available in 50-mg ampules with Cremophor ELfor IV administration in the treatment of acute lymphoblasticleukemia (ALL). The agent is more potent as an inhibitor oftopoisomerase II. The pharmacokinetics of teniposide issimilar to that of etoposide; however, the more lipophilic teniposideis more highly protein bound (99%) and less isexcreted unchanged in the urine (10%–20%). There is alsogreater overall metabolism of teniposide; however, CYP3A4-mediated conversion to the active catechol is slower comparedwith etoposide. Elimination occurs primarily in the urine witha terminal elimination half-life of 5 hours.
Clinical Use
Teniposide is used in combination with other agents for the treatment of refractory childhood acute lymphoblastic leukemia.
Safety Profile
Poison by intraperitoneal and subcutaneous routes. An experimental teratogen. Human systemic effects by ingestion and intravenous route: anorexia, nausea or vomiting, leukopenia, agranulocytosis and aplastic anemia of the blood, bone marrow changes, and hair changes. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of SOx.
Teniposide Preparation Products And Raw materials
Raw materials
Preparation Products
Supplier | Tel | Country | ProdList | Advantage | Inquiry |
---|---|---|---|---|---|
CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
Pharma Affiliates | 172-5066494 | Haryana, India | 6761 | 58 | Inquiry |
career henan chemical co | +86-0371-86658258 +8613203830695 | China | 29888 | 58 | Inquiry |
Xiamen AmoyChem Co., Ltd | +86-592-6051114 +8618959220845 | China | 6387 | 58 | Inquiry |
BOC Sciences | +1-631-485-4226 | United States | 19553 | 58 | Inquiry |
Chongqing Chemdad Co., Ltd | +86-023-6139-8061 +86-86-13650506873 | China | 39916 | 58 | Inquiry |
CONIER CHEM AND PHARMA LIMITED | +8618523575427 | China | 49392 | 58 | Inquiry |
29767-20-2(Teniposide)Related Search:
1of4
chevron_right